DrugPatentWatch Database Preview
JADENU Drug Profile
When do Jadenu patents expire, and when can generic versions of Jadenu launch?
Jadenu is a drug marketed by Novartis Pharms Corp and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.
This drug has seventy-six patent family members in forty-eight countries.
The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for JADENU
| International Patents: | 76 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 40 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for JADENU |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JADENU |
| DailyMed Link: | JADENU at DailyMed |
Pharmacology for JADENU
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity Cytochrome P450 3A4 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 1A2 Inhibitors |
Synonyms for JADENU
| 1044764-54-6 |
| 201530-41-8 |
| 4-((3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid |
| 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid |
| 4-[(3Z,5E)-3,5-Bis(6-Oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, AldrichCPR |
| 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl) |
| 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid |
| 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid |
| 4-{5-[(1E)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-3-[(1Z)-6-OXOCYCLOHEXA-2,4-DIEN-1-YLIDENE]-1,2,4-TRIAZOLIDIN-1-YL}BENZOIC ACID |
| 530D418 |
| AB0073018 |
| AB01565800_02 |
| AB1008603 |
| AC1NUU0E |
| AKOS015855839 |
| AN-5418 |
| BCP9000594 |
| Benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)- |
| C21H15N3O4 |
| CAS-201530-41-8 |
| CGP-72670 |
| D03669 |
| D0Q5UQ |
| DB01609 |
| Deferasirox |
| Deferasirox (Exjade) |
| Deferasirox (JAN/USAN/INN) |
| Deferasirox [USAN:INN:JAN] |
| Deferasirox [USAN:INN] |
| Deferasiroxum |
| Deferasiroxum [INN-Latin] |
| DR002074 |
| DSSTox_CID_28522 |
| DSSTox_GSID_48596 |
| DSSTox_RID_82794 |
| DTXSID1048596 |
| Exjade |
| Exjade (TN) |
| HE323479 |
| HSDB 7844 |
| ICL 670 |
| ICL 670A |
| ICL-670 |
| ICL-670A |
| ICL670 |
| J-013060 |
| Jadenu (TN) |
| Jadenu Sprinkle |
| LS-186571 |
| LS-187785 |
| MFCD09751362 |
| MFCD09951804 |
| NCGC00181754-01 |
| NCGC00263572-01 |
| PubChem20503 |
| s1712 |
| SCHEMBL62042 |
| Tox21_112926 |
| Tox21_112926_1 |
| UNII-V8G4MOF2V9 |
| V0697 |
| V8G4MOF2V9 |
| W-5422 |
| ZINC14880008 |
US Patents and Regulatory Information for JADENU
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for JADENU
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for JADENU
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | ➤ Try a Free Trial |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | ➤ Try a Free Trial |
| ➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for JADENU
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Hungary | 226232 | ➤ Try a Free Trial |
| Costa Rica | 20150467 | ➤ Try a Free Trial |
| Poland | 194758 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for JADENU
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2007001,C0914118 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828 |
| 0914118/01 | Switzerland | ➤ Try a Free Trial | PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005 |
| C 035/2006 | Ireland | ➤ Try a Free Trial | SPC 035/2006: 20070528, EXPIRES: 20210827 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
